Pruritus Therapeutics Industry Forecast 2025-2034: Market Expansion, Trends, and Competitive Landscape

 

The pruritus therapeutics market size has grown strongly in recent years. It will grow from $11.89 billion in 2024 to $12.51 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%.  The growth in the historic period can be attributed to growth in the incidence of pruritus, diverse causes and conditions, rising aging population, and patient quality of life focus

The pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%.  The growth in the forecast period can be attributed to expanding knowledge of pruritus pathophysiology, innovative drug formulations, and delivery, focus on personalized medicine, rise in dermatological research and development, increasing awareness and diagnosis rates, and growing interest in botanical and herbal remedies. Major trends in the forecast period include the development of itch-specific receptor agonists and antagonists, market emphasis on personalized therapeutic approaches, integration of technology in itch monitoring and management, and collaborations for cross-disciplinary research.

Get Your Free Sample of The Global Pruritus Therapeutics  Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

How have varous drivers impacted the growth of the pruritus therapeutics  market?
The rise in the incidence of dermatological disorders is expected to propel the growth of the pruritus therapeutics market going forward. Dermatological disorders refer to skin, hair, nail, and mucous membrane disorders ranging from acne and eczema to skin cancer and fungal infections. The underlying cause of itching often determines the use of pruritus treatments for dermatological illnesses. This condition uses topical treatments, emollients and moisturizers, immunosuppressant medications, and itching medications. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there will be 108,270 reported cases of skin cancer, reflecting a 3.2% increase from the 104,930 cases reported in 2023. Therefore, the rise in the incidence of dermatological disorders is driving the growth of the pruritus therapeutics market.

What are the primary segments of the pruritus therapeutics  market?
The pruritus therapeutics market covered in this report is segmented –
1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetics: Topical Local Anesthetics
4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream
7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which firms are leading the pruritus therapeutics  market?
Major companies operating in the pruritus therapeutics market include  Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

How will industry trends affect the trajectory of the pruritus therapeutics  market?
Major companies operating in the pruritus therapeutics market are focused on developing targeted treatments for rare diseases and specific patient populations. such as non-systemic ileal bile acid transport inhibitor to provide personalized medicine that addresses unmet medical needs. A non-systemic ileal bile acid transport inhibitor is a type of medication that targets bile acid absorption in the intestine without significantly affecting the systemic circulation, thereby minimizing potential side effects. For instance, in June 2023, Ipsen, a France-based pharma company, received the Food and Drug Administration (FDA), a US-based federal agency of the Department of Health and Human Services, approval for Bylvay (odevixibat) for treating cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS). Bylvay, a once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), has minimal systemic exposure and is the first drug approved for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) in the U.S. It was previously approved for PFIC treatment in Europe and is now available by prescription for eligible ALGS patients.

Which geographic trends are shaping the pruritus therapeutics  market, and which region has the highest market share?
North America  was the largest region in the pruritus treatment market in 2024. Asia-Pacific  is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does The Pruritus Therapeutics  Market Report 2025 Offer?
The pruritus therapeutics  market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Pruritus therapeutics refers to the treatments used to address an unpleasant skin sensation that causes an urge to scratch. This treatment is commonly used to stop swelling and inflammation in moderate-to-severe inflammatory skin diseases.

Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11907

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model